*Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital †Department of Laboratory Medicine, Division of Therapeutic Immunology, Karolinska Institutet, Stockholm, Sweden.
J Immunother. 2013 Oct;36(8):432-41. doi: 10.1097/CJI.0b013e3182a802f6.
One disadvantage with umbilical cord blood transplantation is that donor lymphocyte infusion (DLI) for treatment of threatening rejection or relapse of underlying malignant disease is not available. We have previously expanded T cells from the cord blood graft in clinical setting using anti-CD3/CD28 paramagnetic beads and interleukin (IL)-2 for possible future DLI. Here we studied the effect of adding clinical-grade IL-7 to the expansion protocol. T cells were positively selected with anti-CD3/CD28 paramagnetic beads and cultured in increasing concentrations of IL-2 with and without IL-7 (20 ng/mL). After 7 days of expansion, the T cells were analyzed for proliferative capacity and investigated with flow cytometry and Luminex to determine phenotype, cytokine production, and responsiveness to mitogenic stimulus. Cultures with IL-7 had significantly greater proliferation rate, higher CD4/CD8 ratio, a lower percentage of central memory T cells (CD45ROCCR7), and a higher percentage of effector memory T cells (CD45ROCCR7). We assessed the production of IL-2, tumor necrosis factor-α, interferon-γ, and CD107a and found a higher percentage of polyfunctional T cells (positive for 3 to 4 factors) in cells cultured with IL-7. The addition of IL-7 gives a proliferative advantage, also in cultures with a lower dose of IL-2. This could prove advantageous in T-cell culture for adoptive transfer to decrease the risk of apoptosis and other negative effects of cytokine deprivation in vivo. Addition of IL-7 also had an effect on the differentiation status of the cord blood-derived T cells. T cells cultured in IL-7 had more polyfunctional traits, possibly increasing the activity of a putative future umbilical cord blood DLI.
脐带血移植的一个缺点是,不能进行供者淋巴细胞输注(DLI)来治疗潜在恶性疾病的威胁性排斥反应或复发。我们之前已经在临床环境中使用抗 CD3/CD28 超顺磁珠和白细胞介素(IL)-2 从脐带血移植物中扩增 T 细胞,以备将来进行 DLI。在这里,我们研究了在扩增方案中添加临床级 IL-7 的效果。T 细胞用抗 CD3/CD28 超顺磁珠进行阳性选择,并在含有和不含有 IL-7(20ng/mL)的递增浓度的 IL-2 中进行培养。在 7 天的扩增后,分析 T 细胞的增殖能力,并通过流式细胞术和 Luminex 进行检测,以确定表型、细胞因子产生以及对有丝分裂刺激的反应性。含有 IL-7 的培养物具有显著更高的增殖率、更高的 CD4/CD8 比值、更低的中央记忆 T 细胞(CD45ROCCR7)百分比和更高的效应记忆 T 细胞(CD45ROCCR7)百分比。我们评估了 IL-2、肿瘤坏死因子-α、干扰素-γ 和 CD107a 的产生,发现 IL-7 培养的细胞中具有更高百分比的多功能 T 细胞(阳性 3 到 4 个因子)。添加 IL-7 可在较低剂量的 IL-2 培养物中提供增殖优势。这可能有利于 T 细胞培养以进行过继转移,从而降低体内细胞因子剥夺导致凋亡和其他负面效应的风险。添加 IL-7 还对脐带血来源的 T 细胞的分化状态产生影响。在 IL-7 中培养的 T 细胞具有更多的多功能特征,可能会增加未来潜在的脐带血 DLI 的活性。